SLC5A2 and type 2 diabetes mellitus: In patients with type 2 diabetes mellitus, albuminuria decreases by 7–41% after 12 weeks in response to SGLT2 inhibition with empagliflozin, and stays low even after 3 years of treatment in clinical studies [13, 14].